Target Lesion Failure With Current Drug-Eluting Stents
Authors:
- 1 December 2020
- journal article
- research article
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 13 (24) , 2868-2878
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Comparison of the Ultrathin Strut, Biodegradable Polymer Sirolimus-eluting Stent With a Durable Polymer Everolimus-eluting Stent in a Chinese Population: The Randomized BIOFLOW VI TrialClinical Therapeutics, 2020
- Long-Term Safety of Drug-Eluting and Bare-Metal StentsJACC, 2015
- Clinical Outcomes With Bioabsorbable Polymer- Versus Durable Polymer-Based Drug-Eluting and Bare-Metal StentsJACC, 2014
- Effect of Biolimus-Eluting Stents With Biodegradable Polymer vs Bare-Metal Stents on Cardiovascular Events Among Patients With Acute Myocardial InfarctionJAMA, 2012
- Second-Generation Everolimus-Eluting Stents Versus First-Generation Sirolimus-Eluting Stents in Acute Myocardial InfarctionJACC, 2012
- The SPIRIT V Diabetic Study: A randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Liberté paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesionsAmerican Heart Journal, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaborationBMJ, 2009
- Pathology of Drug-Eluting Stents in HumansJACC, 2006
- Simultaneous comparison of multiple treatments: combining direct and indirect evidenceBMJ, 2005